1. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.J Clin Oncol. 2001;19:3685–3691.
2. Sullivan KM, Agura E, Anasetti C, et al. Chronic graftversus-host disease and other late complications of bone marrow transplantation.Semin Hematol. 1991;28:250–259.
3. Sullivan KM. Graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ, eds.Hematopoietic Cell Transplantation, 2nd Edition. Boston: Blackwell Science; 1999;515–536.
4. Woodle ES, Thistlethwaite JR, Gordon JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group.Transplantation. 1996;62: 594–599.
5. Klintmalm GB, Goldstein R, Gonwa T, et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.Transplant Proc. 1993;25:641–643.